Browse

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

DC Field Value Language
dc.contributor.authorLee, Kyung-Hun-
dc.contributor.authorHur, Hyung-Seok-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorLee, Juhee-
dc.contributor.authorKim, Hwang-Phill-
dc.contributor.authorYoon, Young-Kwang-
dc.contributor.authorHan, Sae-Won-
dc.contributor.authorSong, Sang-Hyun-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorBang, Yung-Jue-
dc.date.accessioned2012-06-28T02:07:58Z-
dc.date.available2012-06-28T02:07:58Z-
dc.date.issued2010-12-
dc.identifier.citationCancer Letters, Vol.299 No.1, pp.22-28-
dc.identifier.issn0304-3835-
dc.identifier.other2442-
dc.identifier.urihttps://hdl.handle.net/10371/77724-
dc.description.abstractWe evaluated RAD001 an inhibitor of the mammalian target of rapamycin (mTOR) in human gastric cancer cell lines and determined the molecular mechanisms RAD001 has marked growth inhibitory activity against the SNU-1 and SNU-216 cells It inhibited phosphorylation of mTOR and S6 K and induced Cl cell cycle arrest Synergistic growth inhibitory effects in combination with 5-fluorouracil (5-FU) was identified Furthermore RAD001 conferred sensitivity to 5-FU-resistant cell lines by downregulating thymidylate synthase (TS) In conclusion RAD001 showed growth inhibitory activity against gastric cancer cells and acted synergistically with cytotoxic agents such as 5-FU by downregulating TS (C) 2010 Elsevier Ireland Ltd All rights reserved-
dc.description.sponsorshipThis study was supported by Grant
No. R31-2008-000-10103-0 from the WCU project of the
MEST and the NRF, and by National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of
Korea (0620300-1).
ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER IRELAND LTDko_KR
dc.subjectGastric cancer-
dc.subjectRAD001-
dc.subjectmTOR-
dc.subjectThymidylate synthase-
dc.titleRAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1016/j.canlet.2010.07.020-
dc.citation.journaltitleCancer Letters-
dc.description.citedreferenceCHON HJ, 2009, CANC RES TREAT, V41, P196-
dc.description.citedreferenceCejka D, 2008, ANTICANCER RES, V28, P3801-
dc.description.citedreferenceKim HP, 2008, MOL CANCER THER, V7, P607, DOI 10.1158/1535-7163.MCT-07-2068-
dc.description.citedreferenceCEJKA D, 2008, CANCER BIOL THER, V7, P1377-
dc.description.citedreferencePandyra AA, 2007, J PHARMACOL EXP THER, V322, P123, DOI 10.1124/jpet.106.115394-
dc.description.citedreferenceLang SA, 2007, INT J CANCER, V120, P1803, DOI 10.1002/ijc.22442-
dc.description.citedreferenceWan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990-
dc.description.citedreferenceWendel HG, 2006, CANCER RES, V66, P7639, DOI 10.1158/0008-5472.CAN-06-0419-
dc.description.citedreferenceXi YG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-68-
dc.description.citedreferenceWullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016-
dc.description.citedreferenceO`Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925-
dc.description.citedreferenceOki E, 2005, INT J CANCER, V117, P376, DOI 10.1002/ijc.21170-
dc.description.citedreferenceAjani JA, 2005, J CLIN ONCOL, V23, P5660, DOI 10.1200/JCO.2005.17.376-
dc.description.citedreferenceVignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113-
dc.description.citedreferenceBeuvink I, 2005, CELL, V120, P747-
dc.description.citedreferenceKang HJ, 2005, BRIT J CANCER, V92, P246, DOI 10.1038/sj.bjc.6602336-
dc.description.citedreferenceBjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362-
dc.description.citedreferenceFingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542-
dc.description.citedreferencePanwalkar A, 2004, CANCER-AM CANCER SOC, V100, P657, DOI 10.1002/cncr.20026-
dc.description.citedreferenceNoh WC, 2004, CLIN CANCER RES, V10, P1013-
dc.description.citedreferenceSawyers CL, 2003, CANCER CELL, V4, P343-
dc.description.citedreferenceChu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9-
dc.description.citedreferenceHuang SL, 2003, CANCER BIOL THER, V2, P222-
dc.description.citedreferenceMizutani Y, 2003, CLIN CANCER RES, V9, P1453-
dc.description.citedreferenceKawate H, 2002, J BIOL CHEM, V277, P36304, DOI 10.1074/jbc.M204956200-
dc.description.citedreferenceNomura T, 2002, INT J UROL, V9, P368-
dc.description.citedreferenceSaga Y, 2002, ONCOLOGY-BASEL, V63, P185-
dc.description.citedreferenceGarber K, 2001, J NATL CANCER I, V93, P1517-
dc.description.citedreferenceNeshat MS, 2001, P NATL ACAD SCI USA, V98, P10314-
dc.description.citedreferenceLEICHMAN L, 2001, EUR J SURG S, P43-
dc.description.citedreferenceHidalgo M, 2000, ONCOGENE, V19, P6680-
dc.description.citedreferencePark JG, 1997, INT J CANCER, V70, P443-
dc.description.citedreferenceCOPUR S, 1995, BIOCHEM PHARMACOL, V49, P1419-
dc.description.citedreferenceJOHNSTON PG, 1995, CANCER RES, V55, P1407-
dc.description.citedreferenceCHOU TC, 1994, J NATL CANCER I, V86, P1517-
dc.description.citedreferencePARK JG, 1987, CANCER RES, V47, P5875-
dc.description.citedreferenceCHOU TC, 1984, ADV ENZYME REGUL, V22, P27-
dc.description.tc6-
dc.identifier.scopusid2-s2.0-77957891539-
dc.citation.endpage28-
dc.citation.number1-
dc.citation.startpage22-
dc.citation.volume299-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0304383510003794?via%3Dihub-
dc.identifier.rimsid2442-
dc.identifier.sci000284516800003-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse